Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice

The novel phosphate binder sevelamer has been shown to prevent the progression of aortic and coronary calcification in uremic patients. Whether it also decreases the progression of atheromatous plaques is unknown. The aim of our study was to examine the effect of sevelamer administration on the deve...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2005-11, Vol.112 (18), p.2875-2882
Main Authors: PHAN, Olivier, IVANOVSKI, Ognen, VANHOLDER, Raymond, LACOUR, Bernard, DRüEKE, Tilman B, MASSY, Ziad A, NGUYEN-KHOA, Thao, MOTHU, Nadya, ANGULO, Jesus, WESTENFELD, Ralf, KETTELER, Markus, MEERT, Natalie, MAIZEL, Julien, NIKOLOV, Igor G
Format: Article
Language:English
Subjects:
Animals
Apolipoproteins E - deficiency
Apolipoproteins E - genetics
Atherosclerosis (general aspects, experimental research)
Atherosclerosis - etiology
Atherosclerosis - metabolism
Atherosclerosis - pathology
Atherosclerosis - physiopathology
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Collagen - metabolism
Disease Progression
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Macrophages - pathology
Medical sciences
Mice
Mice, Knockout
Monocytes - pathology
Neurology
Placebos
Polyamines - therapeutic use
Sevelamer
Tyrosine - analogs & derivatives
Tyrosine - metabolism
Uremia - complications
Vascular diseases and vascular malformations of the nervous system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The novel phosphate binder sevelamer has been shown to prevent the progression of aortic and coronary calcification in uremic patients. Whether it also decreases the progression of atheromatous plaques is unknown. The aim of our study was to examine the effect of sevelamer administration on the development of atherosclerosis and aortic calcification in the uremic apolipoprotein E-deficient mouse as an established model of accelerated atherosclerosis. Female mice were randomly assigned to 4 groups: 2 groups of nonuremic mice (sevelamer versus control) and 2 groups of uremic mice (sevelamer versus control). Sevelamer was given at 3% with chow. The increases in serum phosphorus concentration and calcium-phosphorus product observed in uremic control mice were prevented by sevelamer. Serum total cholesterol was increased in the 2 uremic mouse groups and remained unchanged in response to sevelamer. After 8 weeks of sevelamer treatment, uremic mice exhibited a significantly lower degree of atherosclerosis (P
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA105.541854